EN DE
STOCK COMPARISON

Johnson & Johnson vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Johnson & Johnson (JNJ) and Abbott Laboratories (ABT) compare, as of Aug 13, 2026.

As of Aug 13, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Johnson & Johnson trades at $261 versus a fair value of $169 (-35%), while Abbott Laboratories trades at $111 versus $74.79 (-33%).
Johnson & Johnson
JNJ · USD · Health Care
-35%
upside to fair value
overvalued
Price$261
Fair Value$169
Quality81/100
Abbott Laboratories
ABT · USD · Health Care
-33%
upside to fair value
overvalued
Price$111
Fair Value$74.79
Quality67/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Johnson & JohnsonAbbott Laboratories
Valuation
29.4×P/E (TTM)27.7×
6.34×P/S (TTM)3.89×
7.49×P/B3.36×
18.4×EV/EBITDA15.1×
4.95×PEG1.47×
2.0%Dividend yield
$5.20Dividend per share
Profitability
22%Net margin14%
27%Operating margin13%
26%Return on equity12%
8%Return on assets6%
Growth
10%Revenue growth (YoY)8%
5.6%Avg. growth/yr (3Y)0.5%
2.7%Avg. growth/yr (5Y)5.1%
Balance & size
0.48×Debt / equity0.19×
$611BMarket cap$175B
healthyGrowth qualityhealthy

Abbott Laboratories leads: 6 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Johnson & Johnsonof which business quality 76 · market factors 85 Abbott Laboratoriesof which business quality 66 · market factors 54
ProfitabilityMargins and returns on capital today
74
50
Quality GrowthAre margins and returns improving?
73
47
CashflowEarnings quality: real cash, not paper profit
70
71
Fin. StrengthBalance sheet, leverage, solvency risk
72
80
InvestmentDisciplined investing over empire-building
87
65
Low VolatilityCalm price path (market factor)
96
83
MomentumPrice trend over the last 3–12 months (market factor)
72
44
52W MomentumDistance to the 52-week high (market factor)
94
36
Net IssuanceBuybacks instead of dilution
90
84

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Johnson & Johnson

DCF Models$171
Earnings-Based$73.34
Dividend Discount$93.41
Multiples$163
Asset-Based$22.70
Growth DCF$129
Economic Profit$102
Growth Earnings$207

26 of 26 models see the stock below the current price.

Abbott Laboratories

DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Johnson & Johnson
Bear $106Fair Value $169Bull $255
$261 = current price (white tick)
Abbott Laboratories
Bear $51.13Fair Value $74.79Bull $94.43
$111 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Johnson & Johnson · Health Care

Quality score81 · Top 25%
Fair value upside-35% · below median

Abbott Laboratories · Health Care

Quality score67 · Top 25%
Fair value upside-33% · below median

Bottom line

As of Aug 13, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Johnson & Johnson trades at $261 versus a fair value of $169 (-35%), while Abbott Laboratories trades at $111 versus $74.79 (-33%).

Johnson & Johnson has the higher quality score (81/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.